Perspectives in treatment of AL amyloidosis. - Wikidata - awgldk - TriplyDB

Perspectives in treatment of AL amyloidosis.

Perspectives in treatment of AL amyloidosis.

http://www.wikidata.org/entity/Q37045885

about

Fifty years of melphalan use in hematopoietic stem cell transplantation Chronic diarrhea as the initial clinical manifestation of light-chain amyloidosis with cardiac involvement despite negative duodenal and rectal biopsies.Primary amyloidoma of lung treated with radiation: A rare case report.Tyrosine residues mediate fibril formation in a dynamic light chain dimer interface.Updates in cardiac amyloidosis: a review.Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis Amyloid arthropathy mimicking seronegative rheumatoid arthritis in multiple myeloma: case reports and review of the literature.Amyloid and the GI tract.High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains.Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant.Successful long-term outcome of the first combined heart and kidney transplant in a patient with systemic Al amyloidosis.Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis.Amyloidosis presenting in the head and neck: a report of two cases.Guidelines on the diagnosis and investigation of AL amyloidosis.Abstracts Results of autologous stem cell transplantation for AL amyloidosis in one Czech center Hereditary lysozyme amyloidosis - phenotypic heterogeneity and the role of solid organ transplantation

P2860

Q26824498-5E52139B-59D7-4793-B612-5724F54BF8C0 Q33163149-1D7D7A5D-4BFE-46EB-8EA0-50C5475E36A2 Q34453149-25A87688-A5A8-4407-AF0B-F6D246B68D25 Q36201752-4F54F108-9D42-488C-9431-17038431DE50 Q36366356-DEA7D732-F3FA-41F6-96EE-E8FAE6FD0F35 Q36779759-39ADF8E7-6189-47B7-8F3C-E9D2B10C0AAC Q37086690-C7DD925A-D900-4C5A-B306-2FE0546BCA9B Q37634562-B1179399-568B-4D53-83F2-BC67C48371C9 Q37636098-D66FFF41-24E3-4FC9-BEEC-9EABC5733D93 Q41021929-75849960-B659-473F-9500-ABEEC7CE1A89 Q42160574-DAC8C03C-84CF-4DFC-BA7B-072AA1B9F1C2 Q42879120-8C0C7248-FB9E-4BCA-A7D7-64B185F7CD75 Q42932124-9F0F41B6-5465-4BC8-A917-FC3654E4558F Q46152268-C84DDCDD-54BC-4216-9220-BD05DF8474A3 Q53314979-C4817C52-7C88-41BC-9D30-9704F90FB0AD Q55058605-3DA0D212-4074-4FCB-96B2-A4EF4FCD641C Q57259399-F4B9FE0A-0F2E-46CC-A4A7-21E906598160 Q58125071-13BB1143-8BB2-477D-9066-297A8324EB5B Q58853080-B40EFE49-4442-466E-B692-F5A83B7F7E1A

P2860

Perspectives in treatment of AL amyloidosis.

http://www.wikidata.org/entity/Q37045885

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 December 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Perspectives in treatment of AL amyloidosis.

@en

Perspectives in treatment of AL amyloidosis.

@nl

type

label

Perspectives in treatment of AL amyloidosis.

@en

Perspectives in treatment of AL amyloidosis.

@nl

prefLabel

Perspectives in treatment of AL amyloidosis.

@en

Perspectives in treatment of AL amyloidosis.

@nl

P1433

Q37045885-25D5D3BA-E95B-4935-AD85-6507EA41CB7E

P1476

Q37045885-09D4C238-2F65-4B0A-989A-B0E1FECDD72A

P2093

Q37045885-402474AE-BAAD-42A5-8BF0-4596F39C343F

Q37045885-8333A958-2734-41F3-B80D-49DFA8FC8C48

Q37045885-ECD7A31C-BFCD-42E8-9358-714EBBAA14E0

P2860

Q37045885-03A35C4C-C9FC-4211-8C7C-72074A131AC6

Q37045885-0B572AA2-744F-4D65-9A8D-B05FBCA78383

Q37045885-0C4FA2ED-DCBD-4FD3-B0D8-192612194783

Q37045885-0C78C849-0113-49AD-A4A1-B83D476FC3A2

Q37045885-1678F1CB-DA63-4C44-98D5-2D87EC8CD10A

Q37045885-18904A15-2F24-4102-A925-664ECB16B2C6

Q37045885-19AAD973-F501-4ACF-BD63-BEE247947FCC

Q37045885-1B9DE211-6661-4825-8CBA-6C8B8593DDA4

Q37045885-1CEA7FA1-762C-4E03-9FF5-858802817C98

Q37045885-292B1D3D-B9DC-4A0B-8183-6D76E15117EA

P304

Q37045885-69AA7FDB-FD34-447C-84BB-FADBD817FD38

P31

Q37045885-02BDA3B6-0B17-4C92-920B-35C4EE432656

P356

Q37045885-3077D2F0-86B5-49B3-A07A-3BBA026F05E1

P407

Q37045885-B2E5D553-D7A0-4345-9B07-44D9C8F1BCA8

P433

Q37045885-086A7004-2F84-4DC6-B2E3-A0450A915D72

P478

Q37045885-123EC361-B9BE-4CBA-8FCE-154B35F3E8A2

P577

Q37045885-15C722EF-EBBE-440F-937B-2B3EA7AAFDC1

P5875

Q37045885-D13499DE-48C3-4B4C-AAE9-F8151F11CCDB

P698

Q37045885-33C6EF3A-B132-42E5-A9AA-754524408F3C

P356

J.1365-2141.2007.06936.X

P1433

British Journal of Haematology

P1476

Perspectives in treatment of AL amyloidosis.

@en

P2093

Ashutosh D Wechalekar

http://www.w3.org/2001/XMLSchema#string

Julian D Gillmore

http://www.w3.org/2001/XMLSchema#string

Philip N Hawkins

http://www.w3.org/2001/XMLSchema#string

P2860

Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis

Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis

Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis

Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.

Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis.

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.

P304

365-377

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2007.06936.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

140

http://www.w3.org/2001/XMLSchema#string

P577

2007-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5687614

http://www.w3.org/2001/XMLSchema#string

P698

18162121

http://www.w3.org/2001/XMLSchema#string